NCT07474168

T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

An Open-Label, Dose-Escalation Phase I Clinical Study of T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

An open label, dose-escalation clinical study to evaluate the safety, anti-tumor activity and pharmacokinetics/pharmacodynamic (PK/PD) of NW-301VT in subjects with advanced solid tumor.

Detailed description

Using a modified 3+3 dose escalation design, this study will enroll \~9 subjects to characterize the safety and preliminary anti-tumor activity of NW-301VT . Eligible subjects will undergo leukapheresis for autologous cell product manufacturing, and will receive a 3-day lymphodepleting regimen consisting of cyclophosphamide and fludarabine, followed by a single-dose intravenous infusion of NW-301VT. following this intervention, subjects will be monitored for safety and AE, and tumor evaluation will be performed at pre-specified timepoints per protocol.

Conditions

• Tumor

Interventions

Type	Name	Description
DRUG	NW-301VT	TCR-T cell targeting KRAS G12V mutation

Timeline

• Start date: 2025-12-15
• Primary completion: 2027-02-01
• Completion: 2032-02-01
• First posted: 2026-03-16
• Last updated: 2026-03-16

Locations

1 site across 1 country: China